Identification of hub biomarkers and exploring the roles of immunity, M6A, ferroptosis, or cuproptosis in rats with diabetic erectile dysfunction. (24th August 2022)

• Record Type: Journal Article
• Authors: Wang, Yi; Zhang, Xinyu; Chen, Yinhao; Zhu, Bingye; Xing, Qianwei
• Other Names: Rastrelli Giulia guestEditor.; Santi Daniele guestEditor.
• Is Part Of: Andrology. Volume 11:Number 2(2023)
• Page Start: 316
• Page End: 331
• Publication Date: 2022-08-24
• Subjects: biomarkers -- cuproptosis -- diabetic erectile dysfunction -- ferroptosis -- immunity -- m6A; Andrology -- Periodicals; 616.65
• DOI: 10.1111/andr.13265
• Languages: English
• ISSNs: 2047-2919

Abstract

Abstract: Background: Currently, patients with diabetic erectile dysfunction (DMED) were not satisfied with the effects of first‐line phosphodiesterase type 5 inhibitors (PDE5Is). Hence, this paper was designed to mine hub biomarkers in DMED and explore its potential mechanisms. Methods: Gene expression matrix of DMED was downloaded from the gene expression omnibus (GEO; GSE2457) dataset. The top 20 genes were selected based on the connectivity degrees in protein–protein interaction (PPI) network. Functional enrichment analysis was utilized to reveal DMED‐related signaling pathways. We also explored the roles of immunity, m6A, ferroptosis, or cuproptosis in DMED and constructed Sprague Dawley (SD) rats DMED model to verify gene expressions by quantitative real‐time polymerase chain reaction (qRT‐PCR). Results: Based on the threshold, a total of 122 differently expressed genes (DEGs) were identified in DMED, including 39 up‐regulated and 83 down‐regulated genes. Functional enrichment analysis implied that these DEGs were significantly enriched in peroxisome proliferator‐activated receptors, ferroptosis, hypoxia‐inducible factor 1 signaling pathways, and so on. SD rats DMED model was also successfully established by us and validated by intracavernous pressure/mean arterial pressure, Masson's trichrome staining, and immunohistochemical analysis. We further verified the expression of these top 20 genes from the PPI network by qRT‐PCR in the SD rats DMED model and finally identified Sparc, Lox, Srebf1, and Mmp3 as hub biomarkers (all p < 0.05). As for immunity and cuproptosis, our analysis indicated that DMED had nothing to do with them (all p > 0.05). Actually, DMED was markedly associated with m6A regulators and ferroptosis. Conclusions: We identified Sparc, Lox, Srebf1, and Mmp3 as potential hub biomarkers in the SD rats DMED model for future drug development and found its significant associations with m6A regulators and ferroptosis, but not with immunity or cuproptosis.